Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia
Obradović, Marko
(
Avtor
),
Mrhar, Aleš
(
Avtor
),
Kos, Mitja
(
Avtor
)
URL - Predstavitvena datoteka, za dostop obiščite
http://eurpub.oxfordjournals.org/cgi/search?pubdate_year=2010&volume=&firstpage=&DOI=&author1=kos&author2=&title=&andorexacttitle=and&titleabstract=&andorexacttitleabs=and&fulltext=&andorexactfulltext=and&fmonth=Jan&fyear=1991&tmonth=Aug&tyear=2010&fdatedef=1+January+1991&tdatedef=1+August+2010&flag=&RESULTFORMAT=1&hits=10&hitsbrief=25&sortspec=relevance&sortspecbrief=relevance&sendit=Search
Izvleček
Background: The objective of the present study is to evaluate the cost-effectiveness of human papillomavirus (HPV) vaccination alongside cervical cancer screening programme in Slovenia. Methods: A previously published Markov model representing natural history of HPV infection was adapted to Slovenian context. The model followed a cohort of 12-year-old girls to 85-year-old women. Two strategies were compared: HPV vaccination alongside conventional cytological screening versus screening alone. Analysis was performed from the health care payer perspective. Results: Vaccination with screening compared with screening alone was associated with an incremental cost-effectiveness ratio (ICER) of 23 178 EUR per quality adjustedlife-year (QALY) gained and 54 536 EUR per life-year gained (LYG) at the discounting rate of 5%. Sensitivity analyses demonstrated that the ICER was most sensitive to the need for booster dose and to different values of discount rates. In case the booster dose was assumed 10 years after initial vaccination, the ICER value was increased to 58 690 EUR per QALY. On the otherhand, using lower values of discount rates than the base case 5% significantly reduced the ICER value. Conclusion: According to the cost-effectiveness thresholds of 30 000 EUR per QALY which was adopted by the Health Council in Slovenia, HPV vaccination alongside screening programme can be regarded as cost-effective. However, cost-effectiveness of HPV vaccination would become questionable in case a booster dose was needed to provide lifetime protection.
Jezik:
Angleški jezik
Ključne besede:
stroški zdravljenja
,
rak materničnega vratu
,
citološke raziskave
,
HPV
Vrsta gradiva:
Delo ni kategorizirano (r6)
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FFA - Fakulteta za farmacijo
Leto izida:
2010
Št. strani:
str. 415-421
Številčenje:
vol. 20, no. 4
UDK:
615.2
ISSN pri članku:
1101-1262
COBISS.SI-ID:
2834033
Število ogledov:
1488
Število prenosov:
259
Metapodatki:
Skupna ocena:
(0 glasov)
Vaša ocena:
Ocenjevanje je dovoljeno samo
prijavljenim
uporabnikom.
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Objavi na:
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...
Gradivo je del revije
Naslov:
European journal of public health
Skrajšan naslov:
Eur. j. public health
Založnik:
Almqvist & Wiksell International
ISSN:
1101-1262
COBISS.SI-ID:
14341593
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Komentarji
Dodaj komentar
Za komentiranje se morate
prijaviti
.
Komentarji (0)
0 - 0 / 0
Ni komentarjev!
Nazaj